Skip to main content

Merus N.V. (MRUS)

NASDAQ: MRUS · IEX Real-Time Price · USD
24.67 -1.24 (-4.79%)
Dec 3, 2021 4:00 PM EST - Market closed

Company Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.

Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors.

The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease.

In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co.

Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication.

Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies.

The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V.
Merus Logo
CountryNetherlands
Founded2003
IPO DateMay 19, 2016
IndustryBiotechnology
SectorHealth Care
Employees93
CEOSven Lundberg

Contact Details

Address:
Yalelaan 62
Utrecht, Utrecht 3584 CM
Netherlands
Phone31 30 253 8800
Websitemerus.nl

Stock Details

Ticker SymbolMRUS
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001651311

Key Executives

NamePosition
Dr. Sven Ante LundbergChief Executive Officer, President, Principal Financial Officer and Executive Director
Peter B. Silverman J.D.Executive Vice President, General Counsel, Chief Intellectual Property Officer and Head of Utrecht and US Legal
Hui LiuChief Business Officer, Executive Vice President and Head of Merus U.S.
Dr. Hennie HoogenboomCo-Founder and Scientific Advisor
Cornelis Adriaan de Kruif Ph.D.Chief Technology Officer and Senior Vice President
Dr. Cecile A.W. Geuijen Ph.D.Chief Scientific Officer
Jillian ConnellVice President of Investor Relations and Corporate Communications
Alexander Berthold Hendrik Bakker Ph.D.Chief Development Officer and Senior Vice President
Dr. Andrew Joe M.D.Chief Medical Officer
Anne Van der Touw NoordzijCompany Secretary

Latest SEC Filings

DateTypeTitle
Nov 8, 20218-KCurrent report
Nov 8, 2021424B5Prospectus [Rule 424(b)(5)]
Nov 4, 2021424B5Prospectus [Rule 424(b)(5)]
Nov 2, 202110-QQuarterly report [Sections 13 or 15(d)]
Oct 8, 20214Statement of changes in beneficial ownership of securities
Aug 16, 20214Statement of changes in beneficial ownership of securities
Aug 10, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
Aug 5, 202110-QQuarterly report [Sections 13 or 15(d)]
Aug 4, 20214Statement of changes in beneficial ownership of securities
Jul 7, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings